BioMarin Announces Completion of Acquisition of Inozyme BioMarin Pharmaceutical (Nasdaq: BMRN) has completed its acquisition of Inozyme Pharma (Nasdaq: INZY) in an all-cash transaction valued at approximately $270 million, or $4.00 per share. The tender offer, which expired on June 30, 2025, resulted in approximately 70% of Inozyme shares being validly tendered.The strategic acquisition strengthens BioMarin's enzyme therapies portfolio by adding INZ-701, a late-stage enzyme replacement therapy. This investigational treatment targets ENPP1 Deficiency, a rare genetic condition affecting blood vessels, soft tissues, and bones. INZ-701 is designed to restore pyrophosphate and adenosine levels and has potential applications in additional indications including ABCC6 Deficiency and calciphylaxis.Following the merger completion, Inozyme shares have ceased trading on the Nasdaq Global Select Market and will be delisted. The Boston-based Inozyme, with approximately 50 employees, brings expertise in the PPi-Adenosine Pathway research and development to BioMarin's established portfolio of eight commercial therapies.

#BMRN #INZY BioMarin Announces Completion of Acquisition of Inozyme

www.stocktitan.net/news/BMRN/bio-marin-anno...

Inozyme Pharma Halts Annual Meeting as BioMarin Acquisition Nears Completion Latest update on BioMarin's acquisition of Inozyme Pharma impacts stockholder meeting schedule. Key details about the merger timeline and next steps revealed.

#INZY Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

www.stocktitan.net/news/INZY/inozyme-pharma...

Halper Sadeh LLC Launches Investigation on INZY, SVT, HLGN for Shareholder Protection Halper Sadeh LLC, a law firm for investor rights, is probing INZY, SVT, and HLGN for potential securities law violations affecting shareholders.

Halper Sadeh LLC Launches Investigation on INZY, SVT, HLGN for Shareholder Protection #USA #New_York #Investor_Rights #Halper_Sadeh #INZY

Halper Sadeh LLC Launches Investigation into TXNM, SVT, INZY, PTIX Transactions Halper Sadeh LLC is conducting a thorough investigation into several companies, including TXNM and SVT, regarding potential violations of federal securities laws.

Halper Sadeh LLC Launches Investigation into TXNM, SVT, INZY, PTIX Transactions #United_States #New_York #TXNM #SVT #INZY

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #SBSW 8.1x
2. #MRNA 4.4x
3. #INZY 4.1x
4. #QUBT 4.1x
5. #TGLS 3.9x

#OptionFlow #OptionsTrading #Trading

JUST IN: ( NASDAQ: #INZY ) Top Breakout Stocks to Trade: Amesite, Siyata Mobile, Quantum Computing, Archer Aviation, Inozyme Pharma, and Applied Digital

Investigation Launched by Halper Sadeh LLC Regarding Shareholder Rights of CHTR and INZY Halper Sadeh LLC has initiated investigations into Charter Communications and Inozyme Pharma for possible securities law violations. Shareholders encouraged to explore their rights.

Investigation Launched by Halper Sadeh LLC Regarding Shareholder Rights of CHTR and INZY #United_States #New_York #Halper_Sadeh_LLC #CHTR #INZY

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma BioMarin Pharmaceutical (BMRN) has announced the acquisition of Inozyme Pharma for $4.00 per share in an all-cash transaction valued at approximately $270 million. The deal adds INZ-701, a Phase 3 enzyme replacement therapy being developed for ENPP1 Deficiency, to BioMarin's enzyme therapies portfolio. INZ-701 could become the first treatment for this rare genetic condition that affects blood vessels, soft tissues, and bones. The first Phase 3 pivotal data readout in children is expected in early 2026, with potential launch in 2027. The transaction, unanimously approved by both companies' boards, is expected to close in Q3 2025. Phase 1/2 study results showed a favorable safety profile with improvements in pyrophosphate levels, bone mineralization biomarkers, and quality of life.

#BMRN #INZY BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

www.stocktitan.net/news/BMRN/bio-marin-stre...

Breakthrough Clinical Data: Inozyme's ENERGY 3 Trial Reveals First Potential Treatment for ENPP1 Deficiency New ENERGY 3 trial data shows INZ-701 increases phosphate levels by 8.2%, with zero dropouts. First potential therapy for rare bone disease. See full results.

#INZY Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights

www.stocktitan.net/news/INZY/inozyme-pharma...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bearish moving average convergence divergence crossovers, Tue May 13th - #ZTEK #VTYX #TALK #SATL #RLAY #PHVS #OTLY #LWAY #KPTI #INZY #IIIV #HITI #GAIA #ERAS #DOYU #AUPH #UVV #LTC #GRDN #CGAU - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Groundbreaking Research Exposes Urgent Need: 95% of ENPP1 Deficiency Patients Face Life-Threatening Complications New study of 84 patients uncovers crucial patterns in rare bone and cardiovascular disease, revealing 95% develop serious complications by age 55. Full analysis inside.

#INZY Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

www.stocktitan.net/news/INZY/inozyme-pharma...

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights Inozyme Pharma (NASDAQ: INZY) reported its full year 2024 financial results and announced strategic changes. The company completed enrollment in its ENERGY 3 pivotal trial for ENPP1 Deficiency, with topline data expected in Q1 2026. To extend cash runway, Inozyme is implementing a strategic prioritization including a 25% workforce reduction.Financial highlights include: Cash position of $113.1 million as of December 31, 2024R&D expenses increased to $83.2 million from $54.8 million in 2023G&A expenses remained stable at $20.8 millionNet loss widened to $102.0 million ($1.62 per share) compared to $71.2 million ($1.37 per share) in 2023The company reported positive interim results from ENERGY 1 trial and Expanded Access Program in infants and young children with ENPP1 Deficiency. The current cash position is expected to fund operations into Q1 2026.

#INZY Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

www.stocktitan.net/news/INZY/inozyme-pharma...

Inozyme's INZ-701 Treatment Boosts Infant Survival Rate to 80% in ENPP1 Deficiency Trial Breakthrough interim data shows INZ-701 significantly improves survival rates and reduces arterial calcification in ENPP1 Deficiency patients, with positive safety profile in infants.

#INZY Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

www.stocktitan.net/news/INZY/inozyme-pharma...

#INZY Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/INZY/inozyme-pharma...